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Despite the approval of several anti-angiogenic
therapies, clinical results remain unsatisfactory, and
transient benefits are followed by rapid tumor recur-
rence. Here, we demonstrate potent anti-angiogenic
efficacy of the multi-kinase inhibitors nintedanib
and sunitinib in a mouse model of breast cancer.
However, after an initial regression, tumors resume
growth in the absence of active tumor angiogenesis.
Gene expression profiling of tumor cells reveals
metabolic reprogramming toward anaerobic glycol-
ysis. Indeed, combinatorial treatment with a glycol-
ysis inhibitor (3PO) efficiently inhibits tumor growth.
Moreover, tumors establish metabolic symbiosis,
illustrated by the differential expression of MCT1
and MCT4, monocarboxylate transporters active in
lactate exchange in glycolytic tumors. Accordingly,
genetic ablation of MCT4 expression overcomes
adaptive resistance against anti-angiogenic therapy.
Hence, targeting metabolic symbiosis may be an
attractive avenue to avoid resistance development
to anti-angiogenic therapy in patients.
INTRODUCTION
An imbalance between pro- and anti-angiogenic factors inducing
the formation of new blood vessels from a pre-existing vascula-
ture (angiogenesis) has been described as a hallmark of cancer
(Hanahan and Weinberg, 2011). Hence, targeting angiogenesis
might plausibly reduce intra-tumoral levels of oxygen and nutri-
ents, resulting in tumor starvation and thus in reduced tumor
growth (Folkman, 1971). Anti-angiogenic therapies have been
rapidly translated with great expectations from preclinical cancer
models to clinical practice (Carmeliet and Jain, 2011; Crawford
and Ferrara, 2009; Ferrara and Kerbel, 2005). For example,
the identification of vascular endothelial growth factor (VEGF-A)
and its receptors as rate-limiting factors for normal and patho-
logical angiogenesis has led to the development of bevacizumab
(Avastin), a humanized monoclonal antibody targeting VEGF-A
(Ferrara et al., 2004; Ferrara and Kerbel, 2005). Some cancer
types, such as colorectal (Hurwitz et al., 2004), renal cellCe
This is an open access article under the CC BY-N(Motzer et al., 2007), and pancreatic neuroendocrine carci-
nomas (PNETs) (Raymond et al., 2011), have shown encour-
aging responses to this therapeutic strategy. However, numerous
other cancer types, in particular breast cancer, seem to be
poorly responsive to anti-angiogenic regimens. Indeed, metasta-
tic breast cancer patients treated with standard chemotherapy
plus bevacizumab benefit from only 1 or 2 months of progres-
sion-freesurvival. The rapidonset of resistanceevidently prevents
any overall survival benefit (Kerbel, 2009;Miller et al., 2007; Rose,
2011).
These data underline the importance of deciphering themolec-
ular mechanisms underlying intrinsic or adaptive resistance to
anti-angiogenic therapy. When blocking the VEGF-A signaling
axis in preclinicalmodels, e.g., with bevacizumab, tumors escape
by activating alternative pro-angiogenic signaling pathways,
including signaling by fibroblast growth factors (FGFs), platelet-
derived growth factors (PDGFs), Bv8/prokineticin, and inter-
leukin-17 (IL-17) (Bergers and Hanahan, 2008; Casanovas et al.,
2005; Chung et al., 2013; Compagni et al., 2000; Ferrara, 2010).
In order to counteract the activation of these alternative pro-
angiogenic pathways, several multi-kinase inhibitors, targeting
VEGF-dependent and independent pro-angiogenic signaling
pathways, are currently in clinical use or in clinical trials. For
example, sorafenib, a multi-kinase inhibitor targeting RAF, VEGF
receptors (VEGFRs) 1–3, PDGF receptors (PDGFRs) a and b,
c-KIT, and FLT-3, is currently used for the treatment of hepato-
cellular carcinoma. Sunitinib, blocking VEGFR1–3, PDGFRa/b,
c-KIT, and FLT-3, is employed for the treatment of renal cancer.
Both inhibitors show significant anti-tumor efficacy in preclinical
tumor models and in cancer patients; however, they also suffer
from resistance development based on thus far unknownmecha-
nisms (Pa`ez-Ribes et al., 2009; Raymond et al., 2011). Transient
benefits are rapidly followed by tumor recurrence, sometimes
associated with drug resistance and heightened tumor invasive-
ness (Bergers and Hanahan, 2008; Ebos and Kerbel, 2011;
Pa`ez-Ribes et al., 2009; Sennino and McDonald, 2012; Singh
and Ferrara, 2012).
Nintedanib (BIBF-1120) is an even-wider-spectrum angioki-
nase inhibitor targeting VEGFR1–3, PDGFa/b, andFGF receptors
(FGFRs) 1–4, as well as FLT-3 and SRC family kinases (Hilberg
et al., 2008). Nintedanib has recently shown promising results
in pre-clinical models of lung cancer, ductal adenocarcinoma
of the pancreas, and PNET (Awasthi et al., 2015; Bill et al.,
2015; Kutluk Cenik et al., 2013). Furthermore, nintedanib hasll Reports 15, 1161–1174, May 10, 2016 ª 2016 The Authors 1161
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Evasive Resistance to Anti-angio-
genic Therapy
Py2T murine breast cancer cells were implanted
into the mammary fat pad of FVB/N mice and
treated with nintedanib (50 mg/kg daily p.o.) or
vehicle control from day 14 after tumor cell im-
plantation.
(A) Primary tumor growth was monitored by as-
sessing tumor volumes over the time of therapy.
Values represent mean ± SEM. n = 13 mice per
group.
(B) Tumor weights were determined after 7 days of
nintedanib short-term (ST) treatment. n = 6–8 mice
per group.
(C–F) Cell proliferation (C and D) and the incidence
of apoptosis (E and F) were quantified by immu-
nofluorescence staining for phospho-histone 3
(pH3; red) and cleaved caspase-3 (cCasp3; red),
respectively, of tumor sections from ST and LT
vehicle or nintedanib-treated mice. Representa-
tive immunofluorescence microscopy pictures are
shown in (D) and (F). DAPI was used to visualize cell
nuclei. Values represent the number of pH3-posi-
tive (C) and cCasp3-positive (E) cells per area of
each microscopic field of view. n = 5–8 mice per
group.Mann-WhitneyU test. *p<0.05; ***p<0.001;
****p < 0.0001. The scale bars represent 50 mm.
See also Figure S1.demonstrated excellent tolerance and potent activity in a phase I
clinical trial in early HER2-negative breast cancer (Quintela-Fan-
dino et al., 2014) and in a phase III study in non-small-cell
lung cancer (NSCLC), leading to its approval as a second-line
treatment in combination with docetaxel for advanced NSCLC
(McCormack, 2015; Reck et al., 2014).
We have therefore assessed the effects of nintedanib in mouse
modelsof cancer.We report that tumors treatedwithnintedanibor
sunitinib do not revascularize during the development of therapy
resistance. Instead, the cells located in avascular areas escape
the lack of oxygen by shifting their metabolism toward a hypergly-
colytic state and by producing lactate. Conversely, the cells local-
ized in the vicinity of blood vessels utilize the lactate for oxidative
phosphorylation. The data establishmetabolic symbiosis (Porpor-
ato et al., 2011; Sonveaux et al., 2008) as an alternative route1162 Cell Reports 15, 1161–1174, May 10, 2016to develop resistance to anti-angiogenic
therapy inmousemodels of breast cancer
and of insulinoma. Notably, interference
with glycolysis or disruption of metabolic
symbiosis reinstalls nintedanib’s efficacy
in repressing tumor growth.
RESULTS
Py2T Tumors Develop Evasive
Resistance to Anti-angiogenic
Therapy
Nintedanib is a potent angiogenesis in-
hibitor that represses endothelial cell
proliferation and induces their apoptosis(EC50 < 10 nM), yet with limited direct effects on tumor cells (Hil-
berg et al., 2008). A stable murine breast cancer cell line (Py2T)
established from a breast tumor of an MMTV-PyMT transgenic
mouse (Waldmeier et al., 2012) displayed an EC50 of 8 mM
in vitro, which is above the pharmacologically achievable con-
centration in mice (Hilberg et al., 2008; Roth et al., 2009; Fig-
ure S1A). To study the tumor-suppressive efficacy of nintedanib
in vivo, Py2T cells were orthotopically implanted into the mam-
mary fat pad of immune-competent syngeneic FVB/N female
mice. When tumors reached a volume of 15–20 mm3, where
the angiogenic switch had already taken place (Figure S1B),
daily treatment with nintedanib was initiated (50 mg/kg; p.o.).
During the first week of treatment (short-term [ST] treatment),
tumor volumes as well as tumor weights in nintedanib-treated
animals were significantly reduced (Figures 1A and 1B). This
Figure 2. Lack of Tumor Revasculariza-
tion during Resistance against Nintedanib
Therapy
(A and B) Microvessel densities (A) and CD31-
positive area fractions (B) were quantified in Py2T
tumors from mice treated for 1 week (ST) or
3 weeks (LT) with vehicle or nintedanib.
(C) Endothelial cell apoptosis (CD31, green;
cCasp3, red) is shown on representative immuno-
fluorescence picture of a tumor from a 1-week (ST)
nintedanib-treated mouse. DAPI was used to visu-
alize cell nuclei. The scale represents 20 mm.
(D) Quantification of endothelial cell apoptosis
by immunofluorescence co-staining for cCasp3
and CD31 in tumors from ST and LT vehicle or
nintedanib-treated mice.
(E) Quantification of the percentage of CD31-pos-
itive blood vessels that were in contact with NG2-
positive perivascular cells in Py2T tumors from ST
and LT vehicle or nintedanib-treated mice.
(F) The functionality of blood vessels was assessed
by i.v. injection of fluorescein isothiocyanate (FITC)-
lectin into Py2T tumor-bearing mice following ST
or LT vehicle or nintedanib-treatment. Patent,
perfused blood vessels were identified by immu-
nofluorescence staining for CD31 and detection of
FITC-lectin and quantified by counting CD31 and
lectin double-positive blood vessels.
(G) Hypoxic areas were identified and quantified
by immunofluorescence staining for pimonidazole
adducts in Py2T tumors from ST and LT vehicle or
nintedanib-treated mice.
(H) Representative pictures of the immunofluo-
rescence co-staining for pimonidazole adducts
(red) and CD31 (green) on histological sections
of tumors from ST and LT vehicle or nintedanib-
treated mice. DAPI staining visualizes cell nuclei.
The scale bars represent 100 mm.
n=6–8mice per group.Mann-WhitneyU test. n. s.,
non-significant; **p < 0.01; ***p < 0.001; ****p <
0.0001. See also Figure S2.nintedanib-responsive phase was associated with decreased
cell proliferation and increased apoptosis (Figures 1C–1F). How-
ever, after 3 weeks of treatment (long-term [LT] treatment), tu-
mors escaped this therapeutic effect and showed an enhanced
tumor growth with increased cell proliferation and reducedCell Rapoptosis (Figures 1A and 1C–1F).
Apparently, Py2T breast cancer cells
escaped nintedanib treatment despite
its broad range of inhibitory activities.
Evasive Resistance Is Not
Associated with Tumor
Revascularization
Next, we investigated whether angiogen-
esis had been reactivated in LT-treated
Py2T tumors, thereby escaping ninteda-
nib treatment. Intriguingly, microvessel
density was found decreased both after
ST and LT nintedanib regimen, indicatinga potent and stable anti-angiogenic effect of nintedanib, even in
a phase of drug-refractory exponential tumor growth (Figures
2A, 2B, and S2A). The numbers of blood vessels became more
variable following LT nintedanib treatment, potentially indicating
an initiation of revascularization. However, immunofluorescenceeports 15, 1161–1174, May 10, 2016 1163
Figure 3. Tumor Cells Become Hyperglycolytic during Nintedanib Treatment
(A) Differential gene expression between flow-cytometry-isolated LT nintedanib and vehicle-treated tumor cells was assessed by Affymetrix microarray analysis.
The list of differentially expressed genes was subjected to KEGG pathway analysis.
(B) Gene set enrichment analysis (GSEA) between gene expression profiles of either ST or LT nintedanib and vehicle-treated tumor cells. Shown are the
normalized enrichment score (NES) and the false discovery rate (FDR) q value.
(legend continued on next page)
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co-staining for CD31 and cleaved caspase 3 (cCasp3) revealed
increased apoptosis in endothelial cells after ST and LT ninteda-
nib treatment, demonstrating the sustained anti-angiogenic effi-
cacy of nintedanib even after LT treatment (Figures 2C and 2D).
This therapy-resistant tumor growth was not specific for the
multi-kinase inhibitor nintedanib; in a head-to-head comparison,
Py2T tumors treated with nintedanib and sunitinib displayed
comparable tumor growth and reduced microvessel densities
after LT treatment (Figures S2B–S2D).
Next, we assessed whether Py2T tumors compensate for
the lack of blood vessels with increased pericyte coverage. Peri-
cytes promote the maturation and stabilization of blood vessels
through PDGFR signaling and thus influence the responsiveness
to anti-angiogenic therapy (Hellstro¨m et al., 1999). Interestingly,
despite its inhibitory activity on PDGFR signaling, nintedanib did
not affect the pericyte coverage of blood vessels resisting ninte-
danib treatment (Figures 2E and S2E). Nintedanib also did not
affect the functionality of the remaining blood vessels as deter-
mined by the injection of fluorescence-labeled lectin (Figures
2F and S2F). Consistent with decreased tumor perfusion, pimo-
nidazole staining revealed a significant increase in tumor hypoxia
not only in the ST-treated, nintedanib-responsive tumors but
also in the LT-treated, nintedanib-resistant tumors (Figures 2G
and 2H). These data demonstrate a potent anti-angiogenic activ-
ity of nintedanib and suggest a mechanism of therapy resistance
by which tumors escape anti-angiogenic therapy in the absence
of any revascularization.
Tumor Cells Become Hyperglycolytic to Survive Hypoxia
To investigate the molecular mechanisms underlying the resis-
tance against nintedanib treatment, we isolated by flow cytome-
try endothelial and tumor cells from nintedanib-treated and
untreated tumors at different time points of resistance develop-
ment. To facilitate the isolation of tumor cells, Py2T cells were
transduced with a retroviral construct expressing a truncated,
non-functional form of murine CD8a (Misteli et al., 2010).
A CD45CD8+ population could only be identified in Py2T-
CD8a+ tumors and not in wild-type Py2T tumors (Figure S3A). Af-
ter ST (1 week) and LT (3 weeks) treatment with nintedanib,
CD45CD8a+ tumor cells and CD45CD8aCD31+podoplanin
endothelial cells were sorted by flow cytometry (Figures S3B–
S3D). Changes in gene expression were assessed by DNA oligo-
nucleotide microarray analysis. Surprisingly, endothelial cell
gene expression profiles between ST and LT nintedanib-treated
tumors did not markedly differ, mainly reflecting endothelial cells
undergoing apoptosis (data not shown).
In contrast, gene expression analysis of isolated tumor cells
revealed a marked difference between untreated and treated
groups. The genes resulting from the comparison between LT
nintedanib-treated and untreated tumor cells were subjected
to Kyoto Encyclopedia of Genes and Genomes (KEGG)-pathway(C) A set of core glycolysis enzymes was used to perform hierarchical clustering
treated controls.
(D and E) Expression of different glycolysis and mitochondrial-activity-related tra
is shown. Data are normalized to vehicle-treated tumors. Shown are mean ± SEM
**p < 0.01.
See also Figure S3.analysis, which showed an enrichment of metabolic pathways, in
particular glycolysis (Figure 3A). Gene set enrichment analysis
(GSEA) (Subramanian et al., 2005) also showed an enrichment
of glycolysis gene expression, especially when comparing
the gene expression profiles of LT versus untreated tumor
cells, yet also when comparing ST versus untreated tumor cells
(Figure 3B). Glycolysis gene enrichment also became evident
when the gene expression profiles associated with a core set
of glycolytic enzymes were visualized using a heatmap. Indeed,
hierarchical clustering correctly interrelated the three different
treatment conditions (Figure 3C). qRT-PCR analysis confirmed
the upregulated expression of most of the glycolytic enzymes
upon ST and LT nintedanib treatment, whereas the expression
of genes implicated in mitochondrial biogenesis and oxidative
phosphorylation was unaffected (Figures 3D and 3E).
Because nintedanib-treated tumors exhibited enhanced hyp-
oxia compared to size-matched, vehicle-treated tumors (Figures
2G and 2H), we hypothesized that hypoxia could be a determi-
nant of tumor cell heterogeneity and a direct inducer of the glyco-
lytic shift. As expected, when compared with normoxic cultures,
Py2T cells cultured for 3 days in hypoxic conditions (1% O2)
exhibited a significantly increased expression of nine out of ten
glycolysis-related transcripts analyzed (Figure S3E).
Together, the data suggest a metabolic adaptation to anti-
angiogenic therapy, in which hypoxic tumor cells shift to a hyper-
glycolytic state to survive and proliferate at reduced oxygen and
nutrient supply.
Therapy Resistance Establishes Metabolic Symbiosis
Considering the highly glycolytic phenotype of nintedanib-
treated tumor cells, we analyzed lactate production in Py2T
tumors. Total lactate production was not increased in ninteda-
nib-treated tumors compared to vehicle-treated tumors (Fig-
ure S4A), possibly explained by a fast metabolic utilization of
lactate. The alternation between highly hypoxic and normoxic
areas in nintedanib-treated tumors (Figure 2H), together with
comparable levels of lactate between nintedanib and vehicle-
treated tumors, suggested the establishment of lactate-based
metabolic symbiosis (Sonveaux et al., 2008). In such symbiosis,
hypoxic glycolytic cells use glucose to produce high levels of
lactate that is rapidly exported through monocarboxylate trans-
porter 4 (MCT4),mainly a lactate exporter.Oxidative cells located
in perfused areas express MCT1, mainly a lactate importer, al-
lowing them to take up lactate and directly fuel their Krebs cycle.
These cells do not rely on glycolysis, and glucose can bypass
them and diffuse to hypoxic areas, where it is taken up by glyco-
lytic cells expressing high levels of hypoxia-induced glucose
transporter 1 (Glut1) to produce lactate.
We assessed the establishment of metabolic symbiosis during
the development of resistance against nintedanib-mediated
anti-angiogenic therapy in the Py2T transplantation model ofof gene expression profiles derived from LT and ST nintedanib and vehicle-
nscripts in ST (D) and LT (E) nintedanib-treated tumors analyzed by qRT-PCR
. n = 4 mice per group. Mann-Whitney U test. n.s., non-significant; *p < 0.05;
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breast cancer. Immunofluorescence staining for MCT1 and
MCT4 demonstrated a diffuse baseline expression of MCT1
that remained unchanged during nintedanib treatment, whereas
MCT4 was highly expressed in non-vascularized areas of LT
nintedanib-treated tumors and to a lesser extent in ST-treated
tumors (Figures 4A and S4B–S4D). Similar results were observed
in sunitinib-treated tumors (Figure S4E). To assess the generality
of our findings, we analyzed microvessel densities and MCT4
expression in tumors of Rip1Tag2 transgenic mice that have
been treated with nintedanib (Bill et al., 2015). The Rip1Tag2
transgenic mouse model of PNET is highly sensitive to anti-
angiogenic therapies and has been instrumental for compound
testing and subsequent successful translation to the treatment
of patients with PNETs (Tuveson and Hanahan, 2011). With
Rip1Tag2 mice, nintedanib treatment was initiated at 10 weeks
of age, which prolonged median survival from 24 days in con-
trol-treated animals to 55 days in nintedanib-treated animals.
Comparable to the Py2T breast cancer model, Rip1Tag2 mice
also developed resistance to nintedanib therapy and did not
display any revascularization in therapy-refractory tumors (Fig-
ure S4F), and MCT4 expression was also only found in tumors
after prolonged nintedanib treatment (Figure S4G).
To further assess the establishment of metabolic symbiosis in
nintedanib therapy-resistant tumors, we assessed by immuno-
fluorescence microscopy analysis the expression and localiza-
tion of markers for hypoxia (pimonidazole), glucose uptake
(Glut1), lactate export (MCT4), mitochondrial biogenesis, and
oxidative phosphorylation (PGC1a and COX IV; LeBleu et al.,
2014; Wu et al., 1999). Notably, the mean shortest distance be-
tween MCT4-expressing cells and the nearest blood vessel was
increased in LT tumors, although not with statistical significance
(Figure 4B), indicating the expression of MCT4 in hypoxic areas.
Indeed, the expression of hypoxia-induced Glut1 correlated with
the expression of hypoxia-induced MCT4 and with the hypoxia-
marker pimonidazole in the hypoxic areas of nintedanib LT tu-
mors (Figures 4C–4G, S4H, and S4I). The expression of MCT4
co-localized with pimonidazole as well (Figures 4H, 4I, and
S4J). On the other hand, the expression of PGC1a and COX IVFigure 4. Tumors Establish Metabolic Symbiosis to Overcome Ninteda
(A) Representative pictures of combinatorial immunofluorescence staining for MC
either vehicle or nintedanib (50 mg/kg/day) are shown, as indicated. DAPI was u
(B) Quantification of the closest distance separating blood vessels from MCT4+ a
from ST and LT vehicle or nintedanib-treated mice. Note that, in ST vehicle-treate
vessels could not be determined.
(C and D) Quantification of the Glut1+ area fraction (C) and the MCT4+ area frac
Glut1 on Py2T tumors from ST and LT vehicle or nintedanib-treated mice.
(E) Representative microphotographs of immunofluorescence co-staining for M
nintedanib-treated mice. DAPI is used to visualize cell nuclei. The scale bars rep
(F) Quantification of the hypoxic (pimonidazole+) area fraction within Glut1+ are
tumors from ST and LT vehicle or nintedanib-treated mice.
(G) Representative microphotographs of immunofluorescence co-staining for pim
or nintedanib-treated mice. DAPI was used to visualize cell nuclei. The scale bar
(H) Quantification of the MCT4+ area fraction within pimonidazole+ areas by imm
ST and LT vehicle or nintedanib-treated mice.
(I) Representativemicrophotographs of immunofluorescence co-staining for MCT
nintedanib-treated mice. DAPI is used to visualize cell nuclei. The scale bars rep
(J) Representative microphotographs of immunofluorescence co-staining for PG
nintedanib-treated mice. DAPI is used to visualize cell nuclei. The scale bars rep
n = 4 mice per group. Mann-Whitney U test. *p < 0.05; **p < 0.01. See also Figudid not specifically localize with vascularized or non-vascular-
ized areas yet increased in ST and LT nintedanib-treated tu-
mors (Figures S4K and S4N). Curiously, the co-expression of
MCT4 with PGC1a and COX IV was decreased and unchanged,
respectively, in ST nintedanib-treated tumors, yet it was un-
changed with PGC1a and increased with COX IV comparing
LT vehicle and nintedanib-treated tumors (Figures S4L, S4M,
S4O, and S4P). These results suggest a first wave of tumor hyp-
oxia and glycolysis followed by a homeostasis of metabolic
symbiosis between anaerobic glycolysis and aerobic oxidative
phosphorylation during prolonged anti-angiogenic therapy.
Targeting Glycolysis or Metabolic Symbiosis Delays
Resistance Development
The small molecule 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-
one (3PO) inhibits the glycolytic activator phosphofructoki-
nase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) in endothelial
cells (Schoors et al., 2014). Its combined activity as a glycolysis
and endothelial cell inhibitor made it a prime compound to over-
come glycolysis-induced resistance to anti-angiogenic therapy.
Whereas single treatment with nintedanib significantly repressed
tumor growth in Py2T-transplanted mice, single treatment with
3PO only marginally delayed it (Figures 5A and 5B). Notably,
the combined treatment with nintedanib and 3PO showed an
additive effect on tumor growth inhibition. This combined effect
was not mediated by an additive anti-angiogenic effect, because
the microvessel densities between the nintedanib single and the
nintedanib plus 3PO combination treatments were not signifi-
cantly altered (Figure 5C). Consistent with its ability to normalize
blood vessels, single treatment with 3PO significantly increased
pericyte coverage and thus vessel functionality, possibly ex-
plaining the limited repression of tumor growth despite the signif-
icant decrease in microvessel density (Figure 5D; Schoors et al.,
2014). This effect was abrogated upon combined 3PO and ninte-
danib treatment.
To determine the early effects of 3PO treatment on ninteda-
nib-treated tumors, Py2T-transplanted mice were first treated
with nintedanib for 8 days and then subjected to treatmentnib Treatment
T1, MCT4, and CD31 on histological sections of tumors frommice treated with
sed to visualize cell nuclei. The scale bars represent 100 mm.
reas by immunofluorescence co-staining for MCT4 and CD31 on Py2T tumors
d tumors, MCT4 was not significantly expressed and thus the distance to blood
tion within Glut1+ areas (D) by immunofluorescence co-staining for MCT4 and
CT4 and Glut1 on histological sections of tumors from ST and LT vehicle or
resent 100 mm.
as by immunofluorescence co-staining for pimonidazole and Glut1 on Py2T
onidazole and Glut1 on histological sections of tumors from ST and LT vehicle
s represent 100 mm.
unofluorescence co-staining for MCT4 and pimonidazole on Py2T tumors from
4 and pimonidazole on histological sections of tumors fromST and LT vehicle or
resent 100 mm.
C1a and CD31 on histological sections of tumors from ST and LT vehicle or
resent 50 mm.
re S4.
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Figure 5. Targeting Glycolysis or Metabolic
Symbiosis in Combination with Nintedanib
Treatment Delays Tumor Growth
(A and B) Primary tumor growth over time (A)
and tumor weights at the experimental endpoint
(B) of mice treated with either vehicle or ninte-
danib (50 mg/kg/day) in combination with 3PO
(70 mg/kg/day) or solvent are shown. 3PO treat-
ment was initiated 8 days after the initiation of
nintedanib treatment and then continued as
combinatorial treatment (LT treatment). In (A), data
are displayed as mean tumor volumes ± SEM.
(C) Quantification of microvessel densities by
immunofluorescence staining for CD31 on histo-
logical tumor sections from LT nintedanib and
3PO-treated mice. Values represent the number
of counts per each area of microscopic field of
view, and means are displayed. n = 6–8 mice per
group.
(D) Pericyte coverage was assessed by immuno-
fluorescence staining for CD31 and NG2 on his-
tological tumor sections from LT nintedanib and
3PO-treated mice. Values represent the percent-
age of NG2+ blood vessels, and means are
displayed. n = 4–5 mice per group.
(E and F) Primary tumor growth over time (E) and
tumor weights at the experimental endpoint (F) of
mice injected with Py2T wild-type (WT) or Py2T
CRISPR MCT4 no. 1 and no. 2 cells and treated
with either vehicle control or nintedanib
(50 mg/kg/day) are shown. Nintedanib treatment
was initiated 19 days after tumor cell injection,
once the tumors were palpable. Mice injected with
CRISPR MCT4 no. 1 cells presented a delayed
tumor onset and were therefore treated once the
tumors became palpable (days 27–38). In (E), data
are displayed as mean tumor volumes ± SEM. n =
4–7 mice per group.
Mann-Whitney U test. *p < 0.05; **p < 0.01; ***p <
0.001; ****p < 0.0001. See also Figure S5.with 3PO and nintedanib for subsequent 5 days. Whereas ninte-
danib significantly repressed tumor growth upon ST treatment,
3PO treatment did not add further tumor repression (Figures
S5A and S5B). However, the extent of tumor hypoxia and
the rate of tumor cell apoptosis specifically in the hypoxic
tumor areas significantly increased upon combined nintedanib/
3PO treatment (Figures S5C–S5E). Collectively, these results
suggest that the inhibition of glycolysis is one avenue of over-
coming resistance to anti-angiogenic therapy with multi-kinase
inhibitors.1168 Cell Reports 15, 1161–1174, May 10, 2016To determine whether the inhibition
of metabolic symbiosis could overcome
the development of resistance against
anti-angiogenic therapy, we generated
Py2T cell lines that were devoid of MCT4
by CRISPR/Cas9-mediated knockout of
the Slc16a3 gene (MCT4 is known as so-
lute carrier 16 a3 [Slc16a3]). Two stable
cell clones (CRISPR MCT4 no. 1 and
no. 2), which showed targeted recombi-nation in the Slc16a3 gene and did not express MCT4 protein
anymore, were used for further experimentation (Figure S5F).
The loss of MCT4 expression in these clones significantly
repressed tumor growth as compared to wild-type cells under
treatment, with nintedanib treatment leading to an additive effect
in repressing tumor growth kinetics and final tumor weights (Fig-
ures 5E and 5F). These results were confirmed by short hairpin
RNA (shRNA)-mediated ablation of MCT4 expression (shMCT4)
in Py2T cells (Figure S5G). The loss of MCT4 expression in
shMCT4 cell lines significantly retarded tumor growth kinetics
and final tumor weights under treatment with nintedanib as
compared to shCtrl cells (Figures S5G–S5I). However, after a first
delay, shMCT4 tumors resumed growth. Immunofluorescence
staining for CD31 did not reveal any increase in microvessel den-
sity in nintedanib-treated shMCT4 tumors, excluding an escape
route by revascularization (Figure S5J). Instead, we observed
an increase of MCT4 expression both at the protein and mRNA
level in nintedanib-treated shMCT4 tumors (Figures S5K and
S5L), suggesting that cells with poor shRNA-mediated knock-
down efficiency developed a selective growth advantage and eli-
cited tumor recurrence.
Hypoxia-Induced Glycolysis Is Reverted by 3PO and
Loss of MCT4
The results presented above beg the question whether, in Py2T
tumor cells, hypoxia-induced glycolysis is directly affected by
treatment with nintedanib and 3PO or the loss of MCT4 expres-
sion. Thus, we performed extracellular flux analysis by ‘‘Sea-
horse’’ methodology to determine the oxygen consumption
rate (OCR) as a measure of oxidative phosphorylation and the
extracellular acidification rate (ECAR) as a measure of glycol-
ysis. As expected, under hypoxic conditions, Py2T cells ex-
hibited increased ECAR (glycolysis) and decreased OCR (oxida-
tive phosphorylation) as compared to normoxic conditions
(Figures 6A and 6B). When directly quantified, hypoxic cells
had reduced ATP-coupled OCR, increased ECAR, unchanged
glycolytic capacity, and decreased glycolytic reserve as
compared to cells cultured under normoxia (Figures 6C–6F).
To determine any effects of therapeutic treatments on the rates
of glycolysis and oxidative phosphorylation, the ratios between
ECAR and OCR were determined in wild-type or MCT4
knockout Py2T cells cultured under normoxia or hypoxia and
treated with solvent, nintedanib, or 3PO. These experiments re-
vealed that nintedanib did not affect the ratio between ECAR
and OCR (Figure 6G), whereas 3PO reduced this ratio, i.e., it
decreased glycolysis and increased oxidative phosphorylation
under hypoxic, but not normoxic, conditions (Figure 6H). The
genetic ablation of MCT4 expression also reduced ECAR/OCR
only under hypoxic growth conditions (Figure 6I), which also re-
sulted into increased tumor cell apoptosis and cell-cycle arrest
(Figures 6J and 6K).
Taken together, the data show that anti-angiogenic resistance
can occur via the establishment of metabolic symbiosis and that
interfering with metabolic symbiosis can overcome resistance to
anti-angiogenic therapy with multi-kinase inhibitors.
DISCUSSION
In this and in the accompanying reports by Allen et al. (2016); this
issue of Cell Reports and Jime´nez-Valerio et al. (2016); this issue
of Cell Reports, we report the intriguing finding that a glycolytic
shift underlies the development of resistance to anti-angiogenic
therapy with multi-kinase inhibitors. Notably, in response to the
efficient repression of tumor angiogenesis, tumors compartmen-
talize into hypoxic regions at a distance fromblood perfusion and
into normoxic regions in the vicinity of mature and functional
blood vessels. The hypoxic tumor cells exhibit high glucose up-
take by the hypoxia-induced expression of Glut1, and they effi-ciently generate and export lactate by the hypoxia-induced
expression of the lactate exporter MCT4. Conversely, the nor-
moxic tumor cells take up the lactate produced by the hypoxic
tumor cells and oxygen from nearby blood vessels and fuel
both into oxidative phosphorylation (Figure 7). Such aspect of
metabolic intra-tumoral heterogeneity is portrayed by the
concept of metabolic symbiosis (Sonveaux et al., 2008).
Here, we have analyzed the efficacy of the angiokinase inhib-
itors nintedanib and sunitinib in a preclinical mouse model of
breast cancer and in the Rip1Tag2 transgenic mouse model of
pancreatic neuroendocrine cancer. Treatment of Py2T tumor-
bearing mice and of Rip1Tag2 mice with the angiogenesis inhib-
itors has led to a significant therapeutic response, characterized
by increased tumor and endothelial cell apoptosis, decreased
tumor cell proliferation, and reduced tumor size. However,
despite the potent anti-angiogenic efficacies, the treated tumors
rapidly escape therapy. Evasive resistance to anti-angiogenic
therapy has previously been reported to rely partially on the
redundancy of pro-angiogenic growth factors leading to tumor
revascularization (Bergers and Hanahan, 2008; Chung et al.,
2013; Ferrara, 2010). Intriguingly, the nintedanib- and sunitinib-
resistant tumors do not show any evidence of revascularization.
Rather, with the reduction in tumor perfusion, hypoxia is
increased in resistant tumors and microarray gene expression
analysis reveals a metabolic shift to glycolysis in the resistant tu-
mor cells. Indeed, glycolysis and glucose-transport-related
genes are well known targets of hypoxia-induced cellular adap-
tations (Harris, 2002), and glycolysis induction has been recently
described in response to VEGF inhibitors (Curtarello et al., 2015;
Kumar et al., 2013).
The tumor cells’ shift to glycolysis as a mechanism underlying
resistance against anti-angiogenic therapy offers the opportunity
of defeating therapy-resistance by interfering with glycolysis.
Indeed, in this and in the accompanying reports (Allen et al.,
2016; Jime´nez-Valerio et al., 2016), combination therapy
involving angiokinase inhibitors with 3PO (our work), a glycolytic
flux inhibitor (Clem et al., 2008; Schoors et al., 2014), or with ra-
pamycin, an mTOR and glycolysis inhibitor (presented in the
accompanying papers by Allen et al. [2016] and Jime´nez-Valerio
et al. [2016]), surmounts resistance to treatment. However, com-
bination treatment of nintedanib with 2-deoxyglucose, a
competitive inhibitor of the production of glucose-6-phosphate
from glucose (Wick et al., 1955), did not delay tumor growth,
most likely due to the fact that we have been unable to supply
the very high concentrations of 2-deoxyglucose in tumors that
would be pharmacologically active (data not shown). Dichloroa-
cetate (DCA), a drug inhibiting pyruvate dehydrogenase kinase
and thus promoting glucose oxidation over glycolysis by
increasing the pyruvate flux into mitochondria (Michelakis
et al., 2010), also has not shown any effect on tumor growth
(data not shown). Hence, the pharmacological targeting of
glycolysis in the context of anti-angiogenic therapy may be
more complex than anticipated.
Along these lines, despite a clear hypoxia-response pattern to
nintedanib therapy, high-throughput metabolomic analysis of tu-
mor lysates from treated mice has failed to show any significant
differences in central carbon metabolism between nintedanib LT
and untreated tumors (data not shown). However, this snapshotCell Reports 15, 1161–1174, May 10, 2016 1169
(legend on next page)
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Figure 7. Targeting Metabolic Symbiosis
Overcomes Resistance to Anti-angiogenic
Therapy
Anti-angiogenic therapy induces hypoxia and re-
duces the supply of nutrients. As a result, tumor
cells shift their metabolism toward a hyperglycolytic
stateandestablishmetabolic symbiosis: tumorcells
in hypoxic areas upregulate glycolysis, increase
lactate production, and export lactate viaMCT4.On
the other hand, lactate is taken up by tumor cells
in more-oxygenated regions of the tumor and is
directly fueling the citric acid cycle and thus oxida-
tivephosphorylation.Asaconsequence, tumorcells
in normoxic tumor regions reduce glucose con-
sumption, which increases its diffusion distance.
Ablating MCT4 expression (MCT4 KO or shMCT4)
or inhibition of glycolysis (3PO) disrupts this ho-
meostatic interplay and decreases tumor growth.analysis ex vivo may be obscured by the concomitant presence
of cells using hypoxia/glycolysis or oxidative phosphorylation
within the same tumor, thus averaging out the metabolites
specific for the distinct cellular subpopulations. In a comparable
way, metabolic flow analysis with labeled substrates of glycol-
ysis and oxidative phosphorylation is hampered by the lack of
a technique to directly measure the metabolites of localized
cell subpopulations within a tumor. We have thus used estab-
lished markers for angiogenesis, hypoxia, metabolite transport,
and mitochondrial function to visualize the distinct meta-
bolic compartments. Moreover, we have analyzed the hypoxia-
induced metabolic shift between glycolysis and oxidative
phosphorylation in cultured tumor cells by Seahorse technology
and have found that inhibition of glycolysis by 3PO as well as the
genetic ablation of MCT4 expression repress hypoxia-induced
glycolysis and induce cell-cycle arrest and apoptosis.
Regions with higher oxygen partial pressure metabolize
lactate produced in hypoxic areas and thus increase the diffu-
sion capacity of oxygen and glucose. Indeed, increased expres-
sion of MCT4 has been correlated with poor prognosis in
melanoma and breast cancer (Doyen et al., 2014; Ho et al.,
2012). Accordingly, the genetic ablation of MCT4 expression inFigure 6. Glycolysis Induced by Hypoxia Can Be Reverted by Treatme
(A and B) Shown are the measurements of representative oxygen consumption
cultured in normoxic or hypoxic conditions. n = 5.
(C–F) Quantification of ATP-coupled respiration (C), glycolysis (D), glycolytic cap
hypoxic conditions. See Supplemental Experimental Procedures for details. Dat
nificance was calculated using two-way ANOVA test.
(G and H) ECAR/OCR ratio of Py2T cells cultured under normoxic or hypoxic cond
Data are displayed as mean ± SD. n = 4. Two-way ANOVA test.
(I) ECAR/OCR ratio of Py2T WT cells or Py2T CRISPR MCT4 no. 1 and no. 2 cells
SD. n = 4. Two-way ANOVA test.
(J) The percentages of apoptotic Py2TWT cells or Py2T CRISPRMCT4 no. 1 and
flow cytometry analysis of annexin-V-expressing cells. Data are displayed as me
(K) Cell-cycle analysis for Py2TWT cells or Py2T CRISPRMCT4 clones no. 1 and
staining. Data are displayed as mean ± SD. n = 3. Two-way ANOVA test.
*p < 0.05; **p < 0.01.Py2T tumors treated with nintedanib show significantly delayed
tumor growth. Our data therefore suggest that (1) despite the
broad range of activities of the multi-kinase inhibitors nintedanib
and sunitinib, tumors can still escape treatment; (2) nintedanib
and sunitinib resistance does not occur via tumor revasculariza-
tion but is induced by a metabolic shift toward glycolysis and the
establishment of metabolic symbiosis; and (3) nintedanib and
sunitinib treatment should be used in combination with glycol-
ysis/metabolic symbiosis inhibitors for LT efficacy (Figure 7).
Along these lines, it has been recently reported that the genetic
disruption of MCT1 or MCT4 represses breast tumor growth
(Morais-Santos et al., 2015) and sensitizes glycolytic tumor cells
to treatment with phenformin, an inhibitor of mitochondrial com-
plex I (Marchiq and Pouysse´gur, 2016). However, complicating
things, a recent investigation of metabolic changes in tumors
after cessation of sunitinib or sorafenib therapy has revealed a
metabolic shift to lipid synthesis and blockade of lipidogenesis
has inhibited tumor regrowth (Sounni et al., 2014).
In conclusion, the data presented here and in the accompa-
nying reports underscore the variety of evasive responses to
anti-angiogenic and likely to other targeted therapies. The estab-
lishment of metabolic symbiosis adds not only another level ofnt with 3PO or the Loss of MCT4
rates (A; OCRs) and extracellular acidification rates (B; ECARs) of Py2T cells
acity (E), and glycolytic reserve (F) of Py2T cells cultured under normoxic or
a are displayed as mean ± SD. n = 5 (glycolytic reserve: n = 4). Statistical sig-
itions and treated with DMSO, 0.5 mM or 1 mM nintedanib (G), or 5 mM 3PO (H).
cultured under normoxic or hypoxic conditions. Data are displayed as mean ±
no. 2 cells cultured under normoxic or hypoxic conditions were assessed using
an ± SD. n = 3. One-way ANOVA test.
no. 2 cultured under normoxic or hypoxic conditions was performed using EdU
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complexity but also a number of druggable targets to the design
of combinatorial therapies. The results also emphasize the
importance of intra-tumoral heterogeneity as therapy response,
in particular with regard to oxygen and nutrient availability. Such
heterogeneity likely masks critical adaptation mechanisms when
performing cross-sectional analysis without spatial resolution.
EXPERIMENTAL PROCEDURES
Mice
FVB/N mice were kept and bred under specific pathogen-free (SPF) conditions.
The generation and characterization of Rip1Tag2 transgenic mice has been
describedelsewhere (Hanahan, 1985). All experimentswere performed following
the rules and legislations of the Cantonal Veterinary Office and the Swiss Federal
Veterinary Office (SFVO) under license numbers 1878, 1907, and 1908.
Cell Lines and Orthotopic Tumor Cell Transplantation
Py2T murine breast cancer cells were cultured as previously described (Wald-
meier et al., 2012). 53 105 cells were orthotopically injected into the mammary
gland number 9 of 7- to 11-week-old female FVB/N mice under isoflurane/
oxygen anesthesia. Tumor length (l) and width (w) were assessed three times
per week using a vernier caliper, and tumor volume (V) was calculated using
the formula V = 0.543 3 l 3 w2.
Therapy Studies, RNA Isolation, qRT-PCR, Immunofluorescence
Microscopy Analysis, Flow Cytometry, Microarray Analysis, and
Bioinformatic Analysis
See the Supplemental Experimental Procedures.
Establishment of CRISPR MCT4 Cell Lines
Subconfluent Py2T cells were transfected with 2 mg of MCT4CRISPR/Cas9 KO
plasmid and 2 mg ofMCT4HDRplasmid (Santa Cruz Biotechnology; sc-429828
and sc-429828HDR, respectively). Successfully transfected cells were selected
bypuromycin treatment (5mg/ml) andfluorescence-activatedcell sorting (FACS)
sortedbased on their RFPexpression. Single cloneswere derived andvalidated
using PCR primers flanking the sequences targeted by the guide RNAs, subse-
quent sequencing, and western blot analysis. Prior to in vivo experiments, the
RFP and puromycin resistance cassettes were removed using infection with
adenovirus-expressing Cre recombinase (Ad-Cre).
Extracellular Metabolic Flux Analysis
For details, see the Supplemental Information.
Statistical Analysis
Data analysis and graph generation was performed using GraphPad Prism 6
(GraphPad Prism Software). All experiments performed with mouse samples
were analyzed usingMann-Whitney U test. Tumor growth curves are displayed
asmean ±SEM. For immunofluorescence analysis, each data point represents
one field of view and the mean is displayed. N, number of mice per group. Sta-
tistical significance of in vitro experiments was calculated using Student’s
t test or ANOVA test, as indicated in the figure legends. Data are displayed
as mean ± SD. N, number of independent experiments. n.s., non-significant;
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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The accession number for the microarray data reported in this paper have
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GEO: GSE78698.
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